Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Sorafenib in Thyroid Cancer
NCT01141309Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2010
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and sorafenib in thyroid cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 16 weeks. Started Jun 2010; status: active, not recruiting.
02
Drugs
everolimussorafenib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT01141309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01141309.